|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
29 July 2022 |
|
Main ID: |
NCT03290131 |
|
Date of registration:
|
19/09/2017 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
OS440-3004 |
|
Scientific title:
|
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis |
|
Date of first enrolment:
|
January 28, 2018 |
|
Target sample size:
|
536 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT03290131 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
|
|
Phase:
|
Phase 3
|
|
|
Countries of recruitment
|
|
Belarus
|
Bosnia and Herzegovina
|
Bulgaria
|
Croatia
|
Moldova, Republic of
|
Poland
|
Serbia
|
United States
|
|
Contacts
|
|
Name:
|
David Jacobs, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Vice President |
| | |
|
Key inclusion & exclusion criteria
|
|
Health Condition(s) or Problem(s) studied
|
|
Source(s) of Monetary Support
|
|